Back to Search Start Over

Computational Studies Applied to Linalool and Citronellal Derivatives Against Alzheimer's and Parkinson's Disorders: A Review with Experimental Approach.

Authors :
da Silva PR
de Andrade JC
de Sousa NF
Ribeiro Portela AC
Oliveira Pires HF
Bezerra Remígio MCR
Alves DDN
de Andrade HHN
Dias AL
da Silva Stiebbe Salvadori MG
de Oliveira Golzio AMF
de Castro RD
Scotti MT
Bezerra Felipe CF
de Almeida RN
Scotti L
Source :
Current neuropharmacology [Curr Neuropharmacol] 2023; Vol. 21 (4), pp. 842-866.
Publication Year :
2023

Abstract

Alzheimer's and Parkinson's are neurodegenerative disorders that affect a great number of people around the world, seriously compromising the quality of life of individuals, due to motor and cognitive damage. In these diseases, pharmacological treatment is used only to alleviate symptoms. This emphasizes the need to discover alternative molecules for use in prevention. Using Molecular Docking, this review aimed to evaluate the anti-Alzheimer's and anti-Parkinson's activity of linalool and citronellal, as well as their derivatives. Before performing Molecular Docking simulations, the compounds' pharmacokinetic characteristics were evaluated. For Molecular Docking, 7 chemical compounds derived from citronellal, and 10 compounds derived from linalool, and molecular targets involved in Alzheimer's and Parkinson's pathophysiology were selected. According to the Lipinski rules, the compounds under study presented good oral absorption and bioavailability. For toxicity, some tissue irritability was observed. For Parkinson-related targets, the citronellal and linalool derived compounds revealed excellent energetic affinity for α-Synuclein, Adenosine Receptors, Monoamine Oxidase (MAO), and Dopamine D <subscript>1</subscript> receptor proteins. For Alzheimer disease targets, only linalool and its derivatives presented promise against BACE enzyme activity. The compounds studied presented high probability of modulatory activity against the disease targets under study, and are potential candidates for future drugs.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Details

Language :
English
ISSN :
1875-6190
Volume :
21
Issue :
4
Database :
MEDLINE
Journal :
Current neuropharmacology
Publication Type :
Academic Journal
Accession number :
36809939
Full Text :
https://doi.org/10.2174/1570159X21666230221123059